Pharmacologic therapy for inflammatory bowel disease refractory to steroids

Although corticosteroids are an effective treatment for induction of remission in inflammatory bowel disease (IBD), many patients are dependent on or refractory to corticosteroids. This review is based on scrutinizing current literature with emphasis on randomized controlled trials, meta-analyses, and Cochrane reviews on the management of IBD refractory to corticosteroids. Based on this evidence, we propose algorithms and optimization strategies for use of immunomodulator and biologic therapy in IBD refractory to corticosteroids.

[1]  P. Rutgeerts,et al.  Endoscopic and histologic healing of Crohn's (ileo-) colitis with azathioprine. , 1999, Gastrointestinal endoscopy.

[2]  A. Zinsmeister,et al.  The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. , 2001, Gastroenterology.

[3]  S. Hanauer,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[4]  G. Porro,et al.  Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn's disease: a randomised, investigator-blind study. , 2003, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[5]  P. Rutgeerts,et al.  Infliximab maintenance therapy for fistulizing Crohn's disease. , 2004, The New England journal of medicine.

[6]  M. Bala,et al.  Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. , 2005, Gastroenterology.

[7]  Paul Rutgeerts,et al.  Infliximab for induction and maintenance therapy for ulcerative colitis. , 2005, The New England journal of medicine.

[8]  D. Jewell,et al.  Cyclosporine for induction of remission in Crohn's disease. , 2005, The Cochrane database of systematic reviews.

[9]  N. D. de Boer,et al.  Thiopurines in inflammatory bowel disease: pharmacogenetics, therapeutic drug monitoring and clinical recommendations. , 2005, Digestive and Liver Disease.

[10]  Å. Danielsson,et al.  Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. , 2005, Gastroenterology.

[11]  S. Targan,et al.  Natalizumab induction and maintenance therapy for Crohn's disease. , 2005, The New England journal of medicine.

[12]  B. Feagan,et al.  Methotrexate for induction of remission in refractory Crohn's disease. , 2005, The Cochrane database of systematic reviews.

[13]  P. Rutgeerts,et al.  Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. , 2006, Gastrointestinal endoscopy.

[14]  R. Panaccione,et al.  Hematopoietic cell transplantation for Crohn's disease; is it time? , 2006, World journal of gastroenterology.

[15]  W. Sandborn,et al.  Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[16]  P. Rutgeerts,et al.  Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. , 2006, Gastroenterology.

[17]  S. Hanauer,et al.  Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial , 2007, Gut.

[18]  S. Schreiber,et al.  Certolizumab pegol for the treatment of Crohn's disease. , 2007, The New England journal of medicine.

[19]  P. Rutgeerts,et al.  Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. , 2007, Gastroenterology.

[20]  A. Timmer,et al.  Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. , 2007, The Cochrane database of systematic reviews.

[21]  S. Targan,et al.  Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. , 2007, Gastroenterology.

[22]  S. Hanauer,et al.  Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab , 2007, Annals of Internal Medicine.

[23]  G. D'Haens,et al.  Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab: A Randomized Trial , 2008 .

[24]  P. Rutgeerts,et al.  946 Corticosteroids Pose An Increased Risk for Serious Infection: An Interim Safety Analysis of the ENCORE Registry , 2008 .

[25]  J. Mate,et al.  Meta‐analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis , 2009, Alimentary pharmacology & therapeutics.

[26]  S. Hanauer,et al.  Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. , 2009, Gastroenterology.

[27]  J. Macdonald,et al.  Methotrexate for maintenance of remission in Crohn's disease. , 2009, The Cochrane database of systematic reviews.

[28]  M. Silverberg,et al.  Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis , 2009, Gut.

[29]  C. O'Morain,et al.  The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. , 2010, Journal of Crohn's & colitis.

[30]  D. Clifford,et al.  Natalizumab-associated progressive multifocal leukoencephalopathy. , 2012 .

[31]  P. Rutgeerts,et al.  Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. , 2010, Gastroenterology.

[32]  P. Rutgeerts,et al.  T1239 Adalimumab Treatment Results in Deep Remission for Patients With Moderate to Severe Ileocolonic Crohn's Disease: Results From EXTEND , 2010 .

[33]  P. Rutgeerts,et al.  Infliximab, azathioprine, or combination therapy for Crohn's disease. , 2010, The New England journal of medicine.

[34]  S. Schreiber.  Certolizumab pegol for the treatment of Crohn’s disease , 2011, Therapeutic advances in gastroenterology.

[35]  W. Sandborn,et al.  Early use of immunosuppressives or TNF antagonists for the treatment of Crohn's disease: time for a change , 2011, Gut.

[36]  P. Moayyedi,et al.  Efficacy of Immunosuppressive Therapy for Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis , 2011, The American Journal of Gastroenterology.

[37]  S. Travis,et al.  The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organisation: Safety , 2011, The American Journal of Gastroenterology.

[38]  S. Schreiber,et al.  Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial , 2011, Gut.

[39]  S. Schreiber,et al.  The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose, and How to Predict Response? , 2011, The American Journal of Gastroenterology.

[40]  H. Tilg,et al.  Development of the Crohn's disease digestive damage score, the Lémann score , 2010, Inflammatory bowel diseases.

[41]  B. Scallon,et al.  Discovery and mechanism of ustekinumab , 2011, mAbs.

[42]  W. El-Matary,et al.  Systematic review: the role of tacrolimus in the management of Crohn’s disease , 2011, Alimentary pharmacology & therapeutics.

[43]  L. Beaugerie.  Immunosuppression-Related Lymphomas and Cancers in IBD: How Can They Be Prevented? , 2012, Digestive Diseases.

[44]  J. Marshall,et al.  Safety of Cell Therapy with Mesenchymal Stromal Cells (SafeCell): A Systematic Review and Meta-Analysis of Clinical Trials , 2012, PloS one.

[45]  G. D'Haens,et al.  Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. , 2012, Gastroenterology.

[46]  S. Vermeire,et al.  Second European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Current management , 2012 .

[47]  J. Coffey,et al.  Infliximab versus cyclosporine as rescue therapy in acute severe steroid-refractory ulcerative colitis: a systematic review and meta-analysis , 2013, International Journal of Colorectal Disease.

[48]  G. Greenberg,et al.  Ustekinumab induction and maintenance therapy in refractory Crohn's disease. , 2012, The New England journal of medicine.

[49]  S. Vermeire,et al.  Serum Adalimumab Concentration and Clinical Remission in Patients with Crohn's Disease , 2013, Inflammatory bowel diseases.

[50]  J. Satsangi,et al.  9 Clinical and endocopic improvement following hemopoietic stem cell transplantation in the ASTIC trial , 2013 .

[51]  A. Ford,et al.  Opportunistic Infections With Anti-Tumor Necrosis Factor-α Therapy in Inflammatory Bowel Disease: Meta-Analysis of Randomized Controlled Trials , 2013, The American Journal of Gastroenterology.

[52]  P. Rutgeerts,et al.  Vedolizumab as induction and maintenance therapy for ulcerative colitis. , 2013, The New England journal of medicine.

[53]  J. Mate,et al.  Safety of Thiopurine Therapy in Inflammatory Bowel Disease: Long-term Follow-up Study of 3931 Patients , 2013, Inflammatory bowel diseases.

[54]  S. Danese,et al.  ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD). , 2013, Journal of Crohn's & colitis.

[55]  L. Peyrin-Biroulet,et al.  Deep Remission in Inflammatory Bowel Disease: Looking Beyond Symptoms , 2013, Current Gastroenterology Reports.

[56]  Jinshui Zhu,et al.  Efficacy and Safety of Certolizumab Pegol for Crohn’s Disease: A Systematic Review and Meta-Analysis , 2013, Advances in Therapy.

[57]  J. Macdonald,et al.  Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. , 2013, The Cochrane database of systematic reviews.

[58]  Kristin Stephens,et al.  Vedolizumab as induction and maintenance therapy for Crohn's disease. , 2013, The New England journal of medicine.

[59]  H. Tilg,et al.  Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. , 2009, Journal of Crohn's & colitis.

[60]  S. Bonovas,et al.  Biological Agents for Moderately to Severely Active Ulcerative Colitis , 2014, Annals of Internal Medicine.

[61]  C. Siegel,et al.  Systematic review: monotherapy with antitumour necrosis factor α agents versus combination therapy with an immunosuppressive for IBD , 2014, Gut.

[62]  T. Raine.  Vedolizumab for inflammatory bowel disease: Changing the game, or more of the same? , 2014, United European gastroenterology journal.

[63]  E. Louis,et al.  Use of azathioprine in IBD: modern aspects of an old drug , 2014, Gut.

[64]  P. Rutgeerts,et al.  Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. , 2014, Gastroenterology.

[65]  J. Xu,et al.  Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. , 2014, Gastroenterology.

[66]  M. Parkes,et al.  Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease: relapse and recapture rates, with predictive factors in 237 patients , 2014, Alimentary Pharmacology and Therapeutics.

[67]  A. Swaminath,et al.  Use of methotrexate in inflammatory bowel disease in 2014: A User's Guide. , 2014, World journal of gastrointestinal pharmacology and therapeutics.

[68]  P. Rutgeerts,et al.  Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. , 2014, Gastroenterology.

[69]  S. Saini,et al.  Systematic review with network meta‐analysis: the efficacy of anti‐TNF agents for the treatment of Crohn's disease , 2014, Alimentary pharmacology & therapeutics.

[70]  D. Leiman,et al.  Therapy of inflammatory bowel disease: what to expect in the next decade , 2014, Current opinion in gastroenterology.

[71]  P. Rutgeerts,et al.  Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. , 2014, Gastroenterology.

[72]  A. Flores,et al.  Therapy with stem cells in inflammatory bowel disease. , 2014, World journal of gastroenterology.

[73]  A. Cohen,et al.  Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease. , 2014, Gastroenterology.

[74]  S. Saini,et al.  Systematic review with network meta‐analysis: the efficacy of anti‐tumour necrosis factor‐alpha agents for the treatment of ulcerative colitis , 2014, Alimentary pharmacology & therapeutics.

[75]  R. Cross,et al.  Adverse events in IBD: to stop or continue immune suppressant and biologic treatment , 2014, Expert review of gastroenterology & hepatology.

[76]  U. Kopylov,et al.  Optimizing anti-TNF treatments in inflammatory bowel disease. , 2014, Autoimmunity reviews.

[77]  S. Saxena,et al.  The Role of Thiopurines in Reducing the Need for Surgical Resection in Crohn's Disease: A Systematic Review and Meta-Analysis , 2014, The American Journal of Gastroenterology.

[78]  Matthew R. Smith,et al.  Mycophenolate mofetil therapy in the management of inflammatory bowel disease--a retrospective case series and review. , 2014, Journal of Crohn's & colitis.

[79]  K. Farkas,et al.  Ability of different rescue therapies to save the bowel in acute, severe, steroid-refractory ulcerative colitis , 2014, Expert review of gastroenterology & hepatology.

[80]  E. Seidman,et al.  Therapeutic drug monitoring in inflammatory bowel disease , 2014, Annals of gastroenterology.

[81]  D. Rubin,et al.  Rescue Therapy with Cyclosporine or Infliximab is not Associated with an Increased Risk for Postoperative Complications in Patients Hospitalized for Severe Steroid-refractory Ulcerative Colitis , 2014, Inflammatory bowel diseases.

[82]  R. Herrmann,et al.  A phase 2 study of allogeneic mesenchymal stromal cells for luminal Crohn's disease refractory to biologic therapy. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[83]  E. Vasiliauskas,et al.  Long‐term outcomes of thalidomide in refractory Crohn's disease , 2015, Alimentary pharmacology & therapeutics.

[84]  S. Travis,et al.  Conventional drug therapy for inflammatory bowel disease , 2015, Scandinavian journal of gastroenterology.

[85]  P. Rutgeerts,et al.  Role for Therapeutic Drug Monitoring During Induction Therapy with TNF Antagonists in IBD: Evolution in the Definition and Management of Primary Nonresponse , 2015, Inflammatory bowel diseases.

[86]  J. Gisbert,et al.  Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[87]  A. Majeed,et al.  The impact of timing and duration of thiopurine treatment on colectomy in ulcerative colitis: a national population‐based study of incident cases between 1989–2009 , 2015, Alimentary pharmacology & therapeutics.

[88]  G. Rogler,et al.  The role and advances of immunomodulator therapy for inflammatory bowel disease , 2015, Expert review of gastroenterology & hepatology.